About the Webinar
As self-funded employers face soaring specialty costs and hundreds of specialty drugs are expected to launch in the next few years, it’s more important than ever to stay up to date on the latest in the pharmacy benefit pipeline. Join us to hear from Jeff Casberg and Julie Kendle from IPD Analytics as they cover:
- Key biosimilar and generic products that will impact employer costs in 2026;
- How new developments in GLP-1s, changes in rebates and the cash pay market will impact pharmacy benefits;
- How Most Favored Nation pricing and Maximum Fair Price negotiations could reshape pharmacy benefit administration and influence commercial costs over time.